Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> mouse Anti-TCC (Terminal Complement Complex, MAC, Membrane Attack Complex, SC5b-9 Complex) (FITC) Monoclonal Antibody [Clone:aE11]

mouse Anti-TCC (Terminal Complement Complex, MAC, Membrane Attack Complex, SC5b-9 Complex) (FITC) Monoclonal Antibody [Clone:aE11]

Imprimer Imprimer
Identifiez-vous

Référence 298100-100ug

Conditionnement : 100ug

Marque : US Biological

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

298100 TCC (Terminal Complement Complex, MAC, Membrane Attack Complex, SC5b-9 Complex) (FITC)

Clone Type
Monoclonal
Host
mouse
Source
human
Isotype
IgG2a
Grade
Affinity Purified
Applications
FC FLISA IF IHC
Crossreactivity
Eq Hu Po
Shipping Temp
Blue Ice
Storage Temp
-20°C

Monoclonal antibody TCC reacts with a C9 neoantigen of the terminal complement complex (TCC). The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components. C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.

Applications:
Suitable for use in Immunofluorescence, Flow Cytometry, FLISA and Immunohistochemistry. Not suitable for use in Western Blot. Other applications not tested.

Recommended Dilutions:
Flow Cytometry: 1:50
Immunohistochemistry (Frozen/Paraffin): 1:50
Immunofluorescence: 1;50. Frozen sections of 10um were dried, fixed in acetone at 4ºC for 10 minutes, dried and blocked for 20 minutes with PBSA.
Optimal dilutions to be determined by the researcher.

Positive Control:
Mucosa from patients with H. Pylori.

Storage and Stability:
Store product at 4°C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C. Aliquots are stable at -20°C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer.
Caution: FITC conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Product Type: Mab|Isotype: IgG2a|Clone No: aE11|Host: mouse|Source: human|Concentration: ~0.1mg/ml|Form: Supplied as a liquid in PBS, 1% BSA, 0.02% sodium azide. Labeled with Fluorescein isothiocyanate (FITC). |Purity: Purified by Protein G affinity chromatography|Specificity: Recognizes human TCC. Species Crossreactivity: equine and porcine||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a liquid in PBS, 1% BSA, 0.02% sodium azide. Labeled with Fluorescein isothiocyanate (FITC).
Purity
Purified by Protein G affinity chromatography
Specificity
Recognizes human TCC. Species Crossreactivity: equine and porcine
References
1. Mollnes, T et al; Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985, 22: 197. 2. Mollnes, T et al; Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 1985, 22: 183. 3. Pettersen, H et al; Human alveolar macrophages synthesize active complement components C6, C7, and C8 in vitro. Scand J Immunol 1987, 25: 567. 4. Berstad, A et al ; Epithelium related deposition of activated complement in Helicobacter pylori associated gastritis. Gut 1997, 40 :196. 5. Stewart, M et al. Antiphospholipid antibody-dependent C5b-9 formation. BJH 1997, 96:451. 6. Meuwissen, M et al. Colocalisation of intraplauq C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Path 2005, 59:126.